NGF and Alzheimer disease: As reported in a recently published phase II clinical trial, no significant clinical rescue was detected by using AAV vectors expressing human NGF on 49 enrolled AD-diagnosed patients who underwent intracerebral injections of AAV-NGF or sham surgery, respectively (Rafii et al., 2018).